
-
Keros Therapeutics NasdaqGM:KROS Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Location: 1050 Waltham Street, Lexington, MA, 02421, United States | Website: https://www.kerostx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-132.7M
Cash
720.5M
Avg Qtr Burn
N/A
Short % of Float
20.52%
Insider Ownership
2.27%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KER-050 (elritercept) Details Blood disorder, Cancer, Myelodysplastic syndrome | Phase 2 Update | |
KER-050 (elritercept) Details Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer | Phase 2 Update | |
KER-065 Details Duchenne muscular dystrophy, Neuromuscular disease | Phase 2 Initiation | |
KER-065 Details Obesity | Phase 1 Update | |
KER-047 (ALK2 inhibitor) Details Myelodysplastic syndrome, Myelofibrosis | Failed Discontinued | |
KER-012 (cibotercept) Details Pulmonary hypertension, Cardiovascular disease | Failed Discontinued | |
KER-047 (ALK2 inhibitor) Details Fibrodysplasia ossificans progressiva, Anemia | Failed Discontinued |